NasdaqCM:VKTX

Stock Analysis Report

Executive Summary

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Viking Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.1%

VKTX

1.6%

US Biotechs

0.4%

US Market


1 Year Return

-52.7%

VKTX

-7.7%

US Biotechs

6.9%

US Market

Return vs Industry: VKTX underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: VKTX underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

VKTXIndustryMarket
7 Day2.1%1.6%0.4%
30 Day-4.6%-2.9%-1.1%
90 Day-20.5%-1.7%-0.5%
1 Year-52.7%-52.7%-6.9%-7.7%9.3%6.9%
3 Year488.7%488.7%14.7%10.7%45.8%36.4%
5 Yearn/a-2.3%-7.0%62.9%45.1%

Price Volatility Vs. Market

How volatile is Viking Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Viking Therapeutics undervalued compared to its fair value and its price relative to the market?

1.64x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate VKTX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate VKTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VKTX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: VKTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate VKTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VKTX is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Viking Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

-29.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VKTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VKTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VKTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if VKTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if VKTX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if VKTX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Viking Therapeutics performed over the past 5 years?

-0.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VKTX is unprofitable, and losses have increased over the past 5 years at a rate of -0.4% per year.

Accelerating Growth: Unable to compare VKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VKTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: VKTX has a negative Return on Equity (-8.47%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: VKTX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VKTX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Viking Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: VKTX's short term assets ($293.6M) exceeds its short term liabilities ($5.6M)

Long Term Liabilities: VKTX's short term assets (293.6M) exceeds its long term liabilities (513.0K)


Debt to Equity History and Analysis

Debt Level: VKTX is debt free.

Reducing Debt: VKTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: VKTX has a low level of unsold assets or inventory.

Debt Coverage by Assets: VKTX's debt is covered by short term assets (assets are 2644910017959060320.092940x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VKTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: VKTX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -18.2% each year


Next Steps

Dividend

What is Viking Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VKTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VKTX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VKTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VKTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VKTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Viking Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Brian Lian (53yo)

7.1yrs

Tenure

US$1,403,283

Compensation

Dr. Brian Lian, Ph.D., has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian serves as Director of Seelos Therapeutics, Inc. He served as Managi ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Brian's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.8yrs

Average Tenure

53yo

Average Age

Experienced Management: VKTX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

5.4yrs

Average Tenure

59.5yo

Average Age

Experienced Board: VKTX's board of directors are considered experienced (5.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Greg Zante (48yo)

    Senior Vice President of Finance

    • Tenure: 0.2yrs
  • Brian Lian (53yo)

    President

    • Tenure: 7.1yrs
    • Compensation: US$1.40m
  • Michael Morneau (54yo)

    Vice President of Finance & Administration

    • Tenure: 1.5yrs
    • Compensation: US$619.56k
  • Amy Broidrick

    Senior Vice President of Corporate Development

    • Tenure: 2.8yrs
  • Marianne Mancini

    Senior Vice President of Clinical Operations

    • Tenure: 1.8yrs

Board Members

  • Scott Hecker

    Scientific Advisor

    • Tenure: 0yrs
  • Matt Foehr (46yo)

    Director

    • Tenure: 5.4yrs
    • Compensation: US$81.82k
  • J. Singleton (67yo)

    Director

    • Tenure: 5.4yrs
    • Compensation: US$105.22k
  • Stephen Webster (58yo)

    Director

    • Tenure: 5.4yrs
    • Compensation: US$106.79k
  • Charlie Rowland (61yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$104.04k
  • Alan Cherrington

    Scientific Advisor

    • Tenure: 0yrs
  • Zan Fleming

    Scientific Advisor

    • Tenure: 0yrs
  • Brian Lian (53yo)

    President

    • Tenure: 7.1yrs
    • Compensation: US$1.40m
  • David Bullough

    Scientific Advisor

    • Tenure: 0yrs
  • Lawson MacArtney (62yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$121.91k

Company Information

Viking Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Viking Therapeutics, Inc.
  • Ticker: VKTX
  • Exchange: NasdaqCM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$471.896m
  • Shares outstanding: 72.21m
  • Website: https://www.vikingtherapeutics.com

Number of Employees


Location

  • Viking Therapeutics, Inc.
  • 12340 El Camino Real
  • Suite 250
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VKTXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2015
1VTDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2015
0VQALSE (London Stock Exchange)YesCommon StockGBUSDApr 2015

Biography

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally avai ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:21
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.